Vashi Pankaj G, Edwin Persis, Popiel Brenten, Gupta Digant
Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center, 2520 Elisha Ave, Zion, IL, 60099, USA.
BMC Cancer. 2015 Dec 24;15:1012. doi: 10.1186/s12885-015-2043-x.
Serum 25-hydroxyvitamin D [25(OH)D], the major circulating form of vitamin D used for evaluating the vitamin D status of patients, has been associated with survival in a variety of cancers with conflicting evidence. We aimed to investigate this association in newly diagnosed advanced non-small-cell lung cancer (NSCLC) patients.
This was a consecutive cohort of 359 newly diagnosed stages III-IV NSCLC patients who underwent a baseline serum 25(OH)D evaluation prior to receiving any treatment at our institution between January 2008 and December 2010. We used the vitamin D categories of "deficient (<20 ng/ml)" and "not deficient (> = 20 ng/ml)". Cox regression was used to evaluate the prognostic significance of serum 25(OH)D after adjusting for relevant confounders.
Mean age at diagnosis was 57.4 years. Of the 359 patients, 151 (42.1 %) were deficient in vitamin D at the time of diagnosis. The median survival in deficient and not deficient cohorts was 11.7 and 12.8 months respectively (p = 0.06). Season of diagnosis, performance status, smoking status and hospital location significantly predicted vitamin D status. On univariate Cox analysis, gender, stage of disease, hospital location, histologic subtype, subjective global assessment (SGA), performance status, smoking status, body mass index and serum albumin were significantly associated with survival (p <0.05 for all). On multivariate Cox analysis, six variables demonstrated statistically significant associations with survival: stage of disease, hospital location, histologic subtype, SGA, smoking status and serum albumin (p <0.05 for all). Serum vitamin D, which was borderline significant in univariate analysis, lost its significance in multivariate analysis.
We found season of diagnosis, performance status and smoking history to be predictive of vitamin D status. Consistent with previously published research in advanced NSCLC, we did not find any significant association between pre-treatment serum 25(OH)D and survival in our patients.
血清25-羟基维生素D[25(OH)D]是用于评估患者维生素D状态的维生素D主要循环形式,其与多种癌症的生存率相关,但证据相互矛盾。我们旨在研究新诊断的晚期非小细胞肺癌(NSCLC)患者中的这种关联。
这是一项连续队列研究,纳入了2008年1月至2010年12月期间在我们机构接受任何治疗之前接受基线血清25(OH)D评估的359例新诊断的III-IV期NSCLC患者。我们使用“缺乏(<20 ng/ml)”和“不缺乏(>=20 ng/ml)”的维生素D分类。在调整相关混杂因素后,使用Cox回归评估血清25(OH)D的预后意义。
诊断时的平均年龄为57.4岁。在359例患者中,151例(42.1%)在诊断时维生素D缺乏。维生素D缺乏和不缺乏队列的中位生存期分别为11.7个月和12.8个月(p=0.06)。诊断季节、体能状态、吸烟状态和医院位置显著预测维生素D状态。单因素Cox分析显示,性别、疾病分期、医院位置、组织学亚型、主观全面评定(SGA)、体能状态、吸烟状态、体重指数和血清白蛋白与生存率显著相关(均p<0.05)。多因素Cox分析显示,六个变量与生存率有统计学意义的关联:疾病分期、医院位置、组织学亚型、SGA、吸烟状态和血清白蛋白(均p<0.05)。血清维生素D在单因素分析中接近显著,但在多因素分析中失去了显著性。
我们发现诊断季节、体能状态和吸烟史可预测维生素D状态。与先前发表的关于晚期NSCLC的研究一致,我们在患者中未发现治疗前血清25(OH)D与生存率之间存在任何显著关联。